Calcium agonists in hyperparathyroidism

Bioliography

• BOCKAERT J, CLAEYSEN S, BECAMEL Get al.: G protein-coupled receptors: dominant players in cell-cell communication. Int. Rev. CytoL (2002) 212:63–132.
   Google Scholar
• PIERCE KL, PREMONT RT, LEFKOWITZ RJ: Seven-transmembrane receptors. Nat. Rev. MoL Cell. Biol. (2002) 3(9):639–650.
   PubMed Web of Science ®Google Scholar
• BROWN EM: Biology of the extracellular Ca2*-sensing receptor. In: The Principles of Bone Biology (Volume 1, 2nd edn), Bilezikian JP, Raisz LG, Rodan GA (Eds), Academic Press, San Diego, CA, USA (2002): 371–387.
   Google Scholar
• COBURN JW ELANGOVAN L, GOODMAN WG, FRAZAO JM: Calcium-sensing receptor and calcimimetic agents. Kidney Int. SuppL (1999) 73:S52–S58.
   PubMedGoogle Scholar
• BROWN EM, GAMBA G, RICCARDI D et al.: Cloning and characterization of an extracellular Ca(2)-sensing receptor from bovine parathyroid. Nature (1993) 366(6455):575–580.
   PubMed Web of Science ®Google Scholar
• EMANUEL RL, ADLER GK, KIFOR 0 et al.: Calcium-sensing receptor expression and regulation by extracellular calcium in the AtT-20 pituitary cell line. MoL EndocrinoL (1996) 10(5):555–565.
   Google Scholar
• BROWN AJ, ZHONG M, FINCH Jet al.: Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am. J. PhysioL (1996) 270(3, Pt 2):F454–F460.
   Google Scholar
• ROGERS KV, DUNN CK, CONKLIN RL et al.: Calcium receptor messenger ribonucleic acid levels in the parathyroid glands and kidney of vitamin D-deficient rats are not regulated by plasma calcium or 1,25-dihydroxyvitarnin D3. Endocrinology (1995) 136(2):499–504.
   PubMed Web of Science ®Google Scholar
• MATHIAS RS, NGUYEN HT, ZHANG MY, PORTALE AA: Reduced expression of the renal calcium-sensing receptor in rats with experimental chronic renal insufficiency. J. Am. Soc. NephroL (1998) 9(10:2067–2074.
   PubMedGoogle Scholar
• BROWN EM: Physiology and pathophysiology of the extracellular calcium-sensing receptor. Am. J Med. (1999) 106(2):238–253.
   PubMed Web of Science ®Google Scholar
• BAT M, TRIVEDI S, LANE CR et al.: Protein kinase C phosphorylation of threonine at position 888 in Ca2*o-sensing receptor (CaR) inhibits coupling to Ca2* store release. J Biol. Chem. (1998) 273(33):21267–21275.
   PubMed Web of Science ®Google Scholar
• BAT M, QUINN S, TRIVEDI S et al.: Expression and characterization of inactivating and activating mutations in the human Ca2*0-sensing receptor. J. Biol. Chem. (1996) 271(32):19537–19545.
   PubMed Web of Science ®Google Scholar
• YE C, ROGERS K, BAT M et al.: Agonists of the Ca(2.)-sensing receptor (CaR) activate nonselective cation channels in HEK293 cells stably transfected with the human CaR. Biochem. Biophys. Res. Commun. (1996) 226(2):572–579.
   Google Scholar
• BROWN EM, CHEN CJ, KIFOR 0 et aL: Ca2()-sensing, second messengers, and the control of parathyroid hormone secretion. Cell Calcium (1990) 11(5):333–337.
   PubMed Web of Science ®Google Scholar
• AWATA H, HUANG C, HANDLOGTEN ME, MILLER RT: Interaction of the calcium-sensing receptor and filamin, a potential scaffolding protein. Biol. Chem. (2001) 276(37):34871–34879.
   Web of Science ®Google Scholar
• HJALM G, MacLEOD RJ, KIFOR 0 et al.: Filarnin-A binds to the carboxyl-terminal tail of the calcium-sensing receptor, an interaction that participates in CaR-mediated activation of mitogen-activated protein kinase. j Biol. Chem. (2001) 276(37):34880–34887.
   Google Scholar
• KIFOR 0, MacLEOD RJ, DIAZ R et al.: Regulation of MAP kinase by calcium-sensing receptor in bovine parathyroid and CaR-transfected HEK293 cells. Am. J PhysioL Renal. PhysioL (2001) 280(2):F291–F302.
   Google Scholar
• McNEIL SE, HOBSON SA, NIPPER V, RODLAND KD: Functional calcium-sensing receptors in rat fibroblasts are required for activation of SRC kinase and mitogen-activated protein kinase in response to extracellular calcium. J. Biol. Chem. (1998) 273(2):1114–11120.
   PubMed Web of Science ®Google Scholar
• GARRETT JE, CAPUANO IV, HAMMERLAND LG et aL: Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J. Biol. Chem. (1995) 270(21): 12919–12925.
   PubMed Web of Science ®Google Scholar
• FELLNER SK, PARKER L: A Ca(2)-sensing receptor modulates shark rectal gland function. J. Exp. Biol. (2002) 205(13):1889–1897.
   PubMed Web of Science ®Google Scholar
• CHENG SX, OKUDA M, HALL AE et aL: Expression of calcium-sensing receptor in rat colonic epithelium: evidence for modulation of fluid secretion. Am. J. PhysioL Gastrointest. Liver PhysioL (2002) 283(I):G240–G250.
   Google Scholar
• SPURR NK: Genetics of calcium-sensing-regulation of calcium levels in the body. Curr. Opin. PharmacoL (2003) 3(3):291–294.
   PubMed Web of Science ®Google Scholar
• BROWN EM: Extracellular Ca2* sensing, regulation of parathyroid cell function, and role of Ca2* and other ions as extracellular (first) messengers. PhysioL Rev. (1991) 71(2):371–411.
   PubMed Web of Science ®Google Scholar
• BROWN EM, MacLEOD RJ: Extracellular calcium sensing and extracellular calcium signaling. PhysioL Rev. (2001) 81(1):239–297.
   PubMed Web of Science ®Google Scholar
• RICCARDI D, HALL AE, CHATTOPADHYAY Net al.: Localization of the extracellular Ca2./polyvalent cation-sensing protein in rat kidney. Am. J. PhysioL (1998) 274(3, Pt 2):F61I-F622.
   Google Scholar
• CARMELIET G, VAN CROMPHAUT S, DACI E et aL: Disorders of calcium homeostasis. Best Pract. Res. Clin. EndocrinoL Metab. (2003) 17(4):529–546.
   PubMed Web of Science ®Google Scholar
• BROWN EM, POLLAK M, HEBERT SC: The extracellular calcium-sensing receptor: its role in health and disease. Annual Rev. Med. (1998) 49:15–29.
   PubMed Web of Science ®Google Scholar
• HAMMERLAND LG, KRAPCHO KJ, GARRETT JE et aL: Domains determining ligand specificity for Ca2* receptors. MoL PharmacoL (1999) 55(4):642–648.
   PubMed Web of Science ®Google Scholar
• MIKI H, MAERCKLEIN PB, FITZPATRICK LA: Spontaneous oscillations of intracellular calcium in single bovine parathyroid cells may be associated with the inhibition of parathyroid hormone secretion. Endocrinology (1995) 136(7):2954–2959.
   PubMed Web of Science ®Google Scholar
• BREITWIESER GE, GAMA L: Calcium-sensing receptor activation induces intracellular calcium oscillations. Am. J. PhysioL Cell. Physiol. (2001) 280(6):CI412–C1421.
   Google Scholar
• RICCARDI D, PARK J, LEE WS et aL: Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc. NatL Acad. Sci. USA (1995) 92(I):131–135.
   Google Scholar
• RICCARDI D, LEE WS, LEE K et aL: Localization of the extracellular Ca2*-sensing receptor and PTH/PTHrP receptor in rat kidney. Am. J. PhysioL (1996) 271:F951–F956.
   PubMed Web of Science ®Google Scholar
• PEARCE SH, WILLIAMSON C, KIFOR 0 et aL: A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. /V. EngL J. Med. (1996) 335(I5):1115–1122.
   PubMedGoogle Scholar
• THAKKER RV: Disorders of the calcium-sensing receptor. Biochem. Biophys. Acta (1996) 1448:166–170.
   Web of Science ®Google Scholar
• HEBERT SC, BROWN EM, HARRIS HW: Role of the Ca(2)-sensing receptor in divalent mineral ion homeostasis. j Exp. Biol. (1997) 200:(2):295–302.
   PubMed Web of Science ®Google Scholar
• VEZZOLI G, TANINI A, FERRUCCI L et al.: Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J. Am. Soc. NephroL (2002) 13(10):2517–2523.
   PubMed Web of Science ®Google Scholar
• HEATH H 3rd: Clinical spectrum of primary hyperparathyroidism: evolution with changes in medical practice and technology. J. Bone Miner. Res. (1991) 6\(Suppl. 2):563–570.
   Google Scholar
• LEIFSSON BG, AHREN B: Serum calcium and survival in a large health screening program. J. Clin. EndocrinoL Metab. (1996) 81(6):2149–2153.
   PubMed Web of Science ®Google Scholar
• SILVERBERG SJ, BILEZIKIAN JP: Evaluation and management of primary hyperparathyroidism. J. Clin. EndocrinoL Metab. (1996) 81(6):2036–2040.
   PubMed Web of Science ®Google Scholar
• WERMERS RA, KHOSLA S, ATKINSON EJ et al.: The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann. Intern. Med. (1997) 126(6):433–440.
   PubMed Web of Science ®Google Scholar
• URENA P: Use of calcimimetics in uremic patients with secondary hyperparathyroidism: review. Artif Organs (2003) 27(9):759–764.
   PubMed Web of Science ®Google Scholar
• IMANISHI Y, TAHARA H, PALANISAMY N et al.: Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J. Am. Soc. NephroL (2002) 13(6):1490–1498.
   PubMedGoogle Scholar
• BROWN EM, WILSON RE, EASTMAN RC et aL: Abnormal regulation of parathyroid release by calcium in secondary hyperparathyroidism due to chronic renal failure. J. Clin. EndocrinoL Metab. (1982) 54:172–179.
   PubMed Web of Science ®Google Scholar
• ARNOLD A: Molecular mechanisms of parathyroid neoplasia. EndocrinoL Metab. Clin. North Am. (1994) 23(1):93–107.
   PubMed Web of Science ®Google Scholar
• HSI ED, ZUKERBERG LR, YANG WI, ARNOLD A: Cyclin Dl/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J. Clin. EndocrinoL Metab. (1996) 81(5):1736–1739.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKHARAPPA SC, GURU SC, MANICKAM P et aL: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 276(5311):404–407.
   PubMed Web of Science ®Google Scholar
• HEPPNER C, KESTER MB, AGARWAL SK et al.: Somatic mutation of the MENI gene in parathyroid tumours. Nat. Genet. (1997) 16(4):375–378.
   PubMed Web of Science ®Google Scholar
• CRYNS VL, YT SM, TAHARA H et aL: Frequent loss of chromosome arm lp DNA in parathyroid adenomas. Genes Chromosomes Cancer (1995) 13(I):9–17.
   Google Scholar
• HOSOKAWA Y, POLLAK MR, BROWN EM, ARNOLD A: Mutational analysis of the extracellular Ca(2) -sensing receptor gene in human parathyroid tumors. J. Clin. EndocrinoL Metab. (1995) 80(11):3107–3110.
   PubMed Web of Science ®Google Scholar
• FALCHETTI A, BECHERINI L, MARTINETI V et al.: Telomerase repeat amplification protocol (TRAP): A new molecular marker for parathyroid carcinoma. Biochem. Biophys. Res. Commun. (1999) 265(1):252–255.
   PubMed Web of Science ®Google Scholar
• MARX SJ: Familial hypocalciuric hypercalcemia. N. EngL J. Med (1980) 303:810–811.
   PubMed Web of Science ®Google Scholar
• MARX SJ, FRASER D, RAPOPORT A: Familial hypocalciuric hypercalcemia: mild expression of the gene in heterozygotes and severe expression in homozygotes. Am. J. Med. (1985) 78:15–22.
   PubMed Web of Science ®Google Scholar
• CARLING T, SZABO E, BAT M et aL: Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tail of the calcium receptor. j Gun. EndocrinoL Metab. (2000) 85(5):2042–2047.
   PubMed Web of Science ®Google Scholar
• POLLACK ME, BROWN EM, ESTEP HL et al.: Autosomal dominant hypocalcaemia caused by a Ca2*-sensing receptor gene mutation. Nat. Genet. (1994) 8:303–307.
   PubMed Web of Science ®Google Scholar
• FINEGOLD DN, ARMITAGE MM, GALIANI M et al.: Preliminary localization of a gene for autosomal dominant hypoparathyroidism to chromosome 3q13. Pediatr. Res. (1994) 36:414–417.
   PubMed Web of Science ®Google Scholar
• PERRY YM, FINEGOLD DM, ARMITAGE MM et al.: A missense mutation in the Ca-sensing receptor gene causes familial autosomal dominant hypoparathyroidism. Am. J. Hum. Genet. (1994) 55:(Suppl.) (Abstract 17)
   Google Scholar
• CHATTOPADHYAY N, MITHAL A, BROWN EM: The calcium-sensing receptor: a window into physiology and pathophysiology of mineral ion metabolism. Endocr. Rev. (1996) 17:289–307.
   PubMed Web of Science ®Google Scholar
• BROWN E: Mutations in the calcium-sensing receptor and their clinical implications. Horm. Res. (1997) 48:199–208.
   PubMed Web of Science ®Google Scholar
• MARX SJ, AGARWAL SK, KESTER MB et aL: Germline and somatic mutation of the gene for multiple endocrine neoplasia Type 1 (MENI). J. Intern. Med. (1998) 243(6):447–453.
   PubMed Web of Science ®Google Scholar
• FARNEBO F, TEH BT, KYTOLA S et aL: Alterations of the MENI gene in sporadic parathyroid tumors. J. Clin. EndocrinoL Metab. (1998) 83(8):2627–2630.
   PubMed Web of Science ®Google Scholar
• BROWN EM: The pathophysiology of primary hyperparathyroidism. J Bone Miner. Res. (2002) 17\(Supp1.2):N24–N29.
   Google Scholar
• YANO S, SUGIMOTO T, TSUKAMOTO T et aL: Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. (2000) 58(5):1980–1986.
   PubMed Web of Science ®Google Scholar
• BROWN AJ, RITTER CS, FINCH JL, SLATOPOLSKY EA: Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int. (1999) 55(4):I284–1292.
   Google Scholar
• YANO S, SUGIMOTO T, TSUKAMOTO T et aL: Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur. j EndocrinoL (2003) 148(4):403–411.
   PubMed Web of Science ®Google Scholar
• LLACH F: Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences. Kidney Int. (1999) 73:S31–S37.
   Google Scholar
• SLATOPOLSKY E, DUSSO A, BROWN AJ: The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am. J Med. Sci. (1999) 317(6):370–376.
   PubMed Web of Science ®Google Scholar
• LJUNGHALL S, HELLMAN P, RASTAD J, AKERSTROM G: Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture. World J. Surg (1991) 15(6):681–687.
   PubMed Web of Science ®Google Scholar
• THOMPSON NW: Multiple endocrine neoplasia Type I. Surgical therapy. Cancer Treat. Res. (1997) 89:407–419.
   PubMedGoogle Scholar
• HOOGHE L, KINNAERT P: Secondary hyperparathyroidism and parathyroid autotransplantation. Acta Chir. Belg. (1994) 94(5):297–298.
   PubMedGoogle Scholar
• NUSSBAUM SR, THOMPSON AR, HUTCHESON KA, GAZ RD, WANG CA: Intraoperative measurement of parathyroid hormone in the surgical management of hyperparathyroidism. Surgery. (1988) 104(6):1121–1127.
   PubMed Web of Science ®Google Scholar
• DAVIES C, DEMEURE MJ, ST JOHN A,EDIS AJ: Study of intact (1-84) parathyroid hormone secretion in patients undergoing parathyroidectomy. World J. Surg (1990) 14(3):355–359.
   PubMed Web of Science ®Google Scholar
• BERGENFELZ A, NORDEN NE, AHREN B: Intraoperative fall in plasma levels of intact parathyroid hormone after removal of one enlarged parathyroid gland in hyperparathyroid patients. Eur. J. Su. (1991) 157(2):109–112.
   PubMedGoogle Scholar
• RYAN MF, JONES SR, BARNES AD: Clinical evaluation of a rapid parathyroid hormone assay. Ann. Clin. Biochem. (1992) 29(I):48–51.
   Google Scholar
• DUQUENNE M, WERYHA G, KAMINSKY P et al.: Serum parathormone profile during surgical treatment of hyperfunctioning parathyroid adenoma: a multicompartmental model./ Bone Miner. Res. (1994) 9(9):137I-1375.
   Google Scholar
• LOCCHI F, TOMMASI M, BRANDI ML et al.: The importance of the unsuppressed glands in the study of intact parathyroid hormone disappearance after parathyroid adenomectomy. Eur. j EndocrinoL (2001) 144(4):353–362.
   PubMed Web of Science ®Google Scholar
• LEVIN KE, CLARK OH: The reasons for failure in parathyroid operations. Arch. Su. (1989) 124(8):911–914.
   PubMed Web of Science ®Google Scholar
• LUMB GA, STANBURY SW: Parathyroid function in human vitamin D deficiency and vitamin D deficiency in primary hyperparathyroidism. Am. J Med. (1974) 56(6):833–839.
   PubMed Web of Science ®Google Scholar
• CARROLL MF, SCHADE DS: A practical approach to hypercalcemia. Am. Fam. Physician (2003) 67(9):1959–1966.
   PubMed Web of Science ®Google Scholar
• REASNER CA, STONE MD, HOSKING DJ et aL: Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. j Clin. EndocrinoL Metab. (1993) 77(4):1067–1071.
   PubMed Web of Science ®Google Scholar
• ROSSINI M, GATTI D, ISAIA G et aL: Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J. Bone Miner. Res. (2001) 16(I):113–119.
   Google Scholar
• KHAN AA, BILEZIKIAN JP, KUNG AWC et aL: A double blind randomized placebo controlled trial of alendronate in primary hyperparathyroidism. J. Bone Mineral Res. (2001) 16(Suppl. I):5226.
   Google Scholar
• HASSANI S, BRAUNSTEIN GD, SEIBEL MJ et aL: Alendronate therapy of primary hyperparathyroidism. Endocrinologist (2001) 11:459–464.
   Web of Science ®Google Scholar
• SELBY PL, PEACOCK M: Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women. N EngL J Med. (1986) 314(23):1481–1485.
   PubMed Web of Science ®Google Scholar
• MARCUS R: Estrogens and progestins in the management of primari hyperparathyroidism. J. Bone Mineral Res. (1991) 16\(Suppl. 2):5I25–5129.
   Google Scholar
• ARNOLD A, BROWN EM, URENA P et al.: Monoclonality of parathyroid tumors in chronic renal failure. J Clin. Invest. (1995) 95:2047–2053.
   PubMed Web of Science ®Google Scholar
• DRUEKE TB: Parathyroid gland hyperplasia in uremia. Kidney Int. (2001) 59:1182–1183.
   PubMed Web of Science ®Google Scholar
• FUKUDA N, TANAKA H, TOMINAGA Y et aL: Decreased 1,25(OH)2D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. Clin. Invest. (1993)92:1436–1443.
   Google Scholar
• GOGUSEV J, DUCHAMBON P, HORY B et al.: Depressed expression of calcium receptor in parathyroid gland tissue 241 Expert Op/n. Investig. Drugs (2004) 13(3) serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J Kidney Dis. (1998) 31(4):607–617.
   Google Scholar
• NAVEH-MANY T, MARX R, KESHET E et al.: Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J. Clin. Invest. (1990) 86:1968–1975.
   PubMed Web of Science ®Google Scholar
• SZABO A, MERKE J, BEIER E et cll.: 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int. (1989) 35:1049–1056.
   Google Scholar
• LOGHMAN-ADHAM M: Safety of new phosphate binders for chronic renal failure. Drug Saf (2003) 26(15):1093–1115.103.
   Google Scholar
• SLATOPOLSKY E, WEERTS C, NORWOOD K et al.: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int. (1989) 36(5):897–903.
   Google Scholar
• INDRIDASON OS, QUARLES LD:104.Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int. (2000) 57(1):282–292.105.
   Google Scholar
• RUDNICKI M, HOJSTED J, PETERSEN LJ et al.: Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients. Nephron (1993) 65:369-374. 106.
   Google Scholar
• HSU CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am. J. Kidney Dis. (1997) 29(4):641–649.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM J: What is the optimal regimen for vitamin D? Kidney Int. (1999) 56:S59–S64.
   Google Scholar
• QUARLES LD, YOHAY DA, CARROLL BA et al.: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. (1994) 45(6):1710–1721.
   PubMed Web of Science ®Google Scholar
• GOODMAN WG, RAMIREZ JA, BELIN TR et al.: Development of adynarnic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. (1994) 46(4):1160–1166.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, PORT FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J Kidney Dis. (2000) 35(6):1226–1237.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of proliferation of low calcium diet-induced hyperparathyroidism in rats. Endocrinology
   Google Scholar
• GANESH SK, STACK AG, LEVIN NW et al.: Association of elevated serum P0(4), Ca x P0(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am. Soc. NephroL (2001) 12(10):2131–2138.
   PubMed Web of Science ®Google Scholar
• GUERIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end-stage renal disease. NephroL Dial. Transplant. (2000) 15(7):1014–1021.
   PubMed Web of Science ®Google Scholar
• CHERTOW GM, BURKE SK, RAGGI P: Sevelarner attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62(1):245–252.
   PubMed Web of Science ®Google Scholar
• GOODMAN WG, RAMIREZ JA, BELIN TR et al.: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. (1994) 46(4):1160–1166.
   PubMed Web of Science ®Google Scholar
• INDRIDASON OS, QUARLES LD: Prevention and management of renal osteodystrophy in dialysis patients. In: Renal Osteodystrophy. Bushinski DA (Ed.), Philadelphia, Lippincott-Raven, Philadelphia, PA, USA (1997):445–472.
   Google Scholar
• FLORIO T, YAO H, CAREY KD et aL: Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). MoL EndocrinoL (1999) 13(1):24–37.
   PubMed Web of Science ®Google Scholar
• ALDERTON F, HUMPHREY PP, SELLERS LA: High-intensity p38 kinase activity is critical for p21(cip1) induction and the antiproliferative function of G(i) protein-coupled receptors. MoL PharmacoL (2001) 59(5):1119–1128.
   PubMed Web of Science ®Google Scholar
• SAKAGUCHI K: Acidic fibroblast growth factor autocrine system as a mediator of calcium-regulated parathyroid cell growth. Biol. Chem. (1992) 267(34):24554–24562.
   Web of Science ®Google Scholar
• KANESAKA Y, TOKUNAGA H, IWASHITA K et al.: Endothelin receptor antagonist prevents parathyroid cell of patients with hyperparathyroidism. Kidney Int. (1997) 51:328-336. (2001) 142(1):407–413.
   Google Scholar
• MATSUSHITA H, HARA M, ENDO Y et al.: Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone-related protein in secondary parathyroid hyperplasia. Kidney Int. (1999) 55(1):130–138.
   PubMed Web of Science ®Google Scholar
• COZZOLINO M, LU Y, FINCH J et cll.: p21WAF1 and TGF-a mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int. (2001) 60(6):2109–2117.
   Google Scholar
• WADA M, NAGANO N: Control of parathyroid cell growth by calcimimetics. NephroL Dial. Transplant. (2003) 18 (Suppl. 3) :iii13-iii17.
   Google Scholar
• COHEN A, SILVERBERG SJ: Calcimimetics: therapeutic potential in hyperparathyroidism. Curr. Opin. PharmacoL (2002) 2(6):734–739.
   PubMed Web of Science ®Google Scholar
• NEMETH EF, STEFFEY ME, FOX J: The parathyroid calcium receptor: a novel therapeutic target for treating hyperparathyroidism. Pediatr. NephroL (1996) 10(3):275–279.
   PubMed Web of Science ®Google Scholar
• RAY K, NORTHUP J: Evidence for distinct cation and calcimimetic compound (NPS 568) recognition domains in the transmembrane regions of the human Ca2* receptor. J. Biol. Chem. (2002) 277(20:18908–18913.
   PubMedGoogle Scholar
• NEMETH EF, STEFFEY ME, HAMMERLAND LG et al.: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. NatL Acad. Sci. USA (1998) 95(7):4040–4045.
   PubMed Web of Science ®Google Scholar
• HAMMERLAND LG, GARRETT JE, HUNG BC et al.: Allosteric activation of the Ca2* receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. MoL PharmacoL (1998) 53(6):1083–1088.
   PubMed Web of Science ®Google Scholar
• OTT SM: Calcimimetics - new drugs with the potential to control hyperparathyroidism. j Clin. EndocrinoL Metab. (1998) 83(4):1080–1082.
   PubMed Web of Science ®Google Scholar
• MIEDLICH S, GAMA L, BREITWIESER GE: Calcium sensing receptor activation by a calcimimetic suggests a link between cooperativity and intracellular calcium oscillations. J BioL Chem. (2002) 277(51):49691–49699.
   PubMed Web of Science ®Google Scholar
• ZHANG Z, JIANG Y, QUINN SJ et al.: L-phenylalanine and NPS R-467 synergistically potentiate the function of the extracellular calcium-sensing receptor GOODMAN WG, GOLDIN J, KUIZON BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. EngL J. Med. (2000) 342(20):1478–1483. 242 Expert Op/n. Investig. Drugs (2004) 13(3) through distinct sites. J Biol. Chem. (2002) 277(37):33736–33741.
   Google Scholar
• LI YC, AMLING M, PIRRO AE et al.: Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology (1998) 139(10): 4391–4396.
   PubMed Web of Science ®Google Scholar
• WADA M, NAGANO N, FURUYA Y et al.: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int. (2000) 57(1):50–58.
   PubMed Web of Science ®Google Scholar
• ANTONSEN JE, SHERRARD DJ, ANDRESS DL: A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int. (1998) 53(1):223–227.
   PubMed Web of Science ®Google Scholar
• NEMETH EF: Calcium receptors as novel drug targets, In: Principles of Bone Biology (1st edn), Bilezikian JP, Raisz LG, Rodan GA (Eds). San Diego, CA, USA Academic Press (1996):1019–1035.
   Google Scholar
• COBURN JW, BARRI T, TURNER SA et al.: Single doses of the calcimimetic AMG 073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism. J Am. Soc. NephroL (2000) 11:573.
   Google Scholar
• GOODMAN WG, TURNER SA, BLAISDELL PW et al.: Multiple doses of the calcimimetic AMG 073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism. J Am. Soc. NephroL (2000) 11:576.
   Google Scholar
• LINDBERG JS, MOE SM, GOODMAN WG et al.: The calcimimetic AMG 073 reduce parathyroid hormone (PTH), phosphorus, and calcium x phosphorus product in patients with ESRD and secondary hyperparathyroidism. J Am. Soc. NephroL (2000) 11:578A.
   Google Scholar
• STEFFEY ME, FOX J, VANWAGENEN BC et al.: Calcimimetics: structurally and mechanistically novel compounds that inhibit hormone secretion from parathyroid cells. J Bone Mineral Res. (1993) 8\(Suppl. 1):5175.
   Google Scholar
• FOX J, LOWE SH, PETTY BA, NEMETH EF: NPS R-568: a Type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J PharmacoL Exp. Ther. (1999) 290(2):473–479.
   PubMed Web of Science ®Google Scholar
• FOX J, LOWE SH, CONKLIN RL et ell.: Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. J. PharmacoL Exp. Ther. (1999) 290(2):480–486.
   Google Scholar
• WADA M, FURUYA Y, SAKIYAMA J et al.: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J. Clin. Invest. (1997) 100(12):2977–2983.
   PubMed Web of Science ®Google Scholar
• CHIN J, MILLER SC, WADA Metal.: Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats./ Am. Soc. NephroL (2000) 11(5):903–911.
   Google Scholar
• WADA M, ISHII H, FURUYA Y et aL: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. (1998) 53(2):448–453.
   PubMed Web of Science ®Google Scholar
• ISHII H, WADA M, FURUYA Y et aL: Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone (2000) 26(2):175–182.
   PubMed Web of Science ®Google Scholar
• HEATH HI, SANGUINETTI EL, OGELSBY S, MARRIOTT TB: Inhibition of human parathyroid hormone secretion in vivo by NPS R-568, a calcimimetic drug that targets the parathyroid cell-surface calcium receptor. Bone (1995) 16:85S.
   PubMedGoogle Scholar
• SILVERBERG SJ, BONE HG 3rd, MARRIOTT TB et al.: Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N EngL J. Med. (1997) 337(20:1506–1510.
   Google Scholar
• AKIZAWA T, SUZUKI M, TOMINAGAY et al.: Acute effects of calcimimetic agent (CA) on hemodialysis (HD) patients with secondary hyperparathyroidism (2HPT). Am. J. Soc. NephroL (1998) 9:561 (Abstract).
   Google Scholar
• GOODMAN WG, FRAZAO JM, GOODKIN DA et al.: A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int. (2000) 58(1):436–445.
   PubMed Web of Science ®Google Scholar
• GOODMAN WG: Recent developments in the management of secondary hyperparathyroidism. Kidney Int. (2001) 59(3):1187–1201.
   PubMed Web of Science ®Google Scholar
• COBURN JW, MAUNG HM: Calcimimetic agents and the calcium-sensing receptor. Curr. Opin. NephroL Hypertens. (2000) 9(2):123–132.
   PubMed Web of Science ®Google Scholar
• FRANCESCHINI N, JOY MS, KSHIRSAGAR A: Cinacalcet HC1: a calcimimetic agent for the management of primary and secondary hyperparathyroidism. Expert Opin. Invest* Drugs (2003) 12(8):1413–1421.
   PubMed Web of Science ®Google Scholar
• RACKE FK, NEMETH EF: Protein kinase C modulates hormone secretion regulated by extracellular polycations in bovine parathyroid cells. J. Physid. (1993) 468:163–176.
   PubMed Web of Science ®Google Scholar
• RACKE FK, NEMETH EF: Cytosolic calcium homeostasis in bovine parathyroid cells and its modulation by protein kinase C. J PhysioL (1993) 468:141–162.
   PubMed Web of Science ®Google Scholar
• NEMETH EF, HEATON WH, MILLER M et al.: Pharmacodynarnics of the Type II Calcimimetic Compound, Cinacalcet HC1. j PharmacoL Exp. Ther. (2003) 308(2):627–635.
   PubMed Web of Science ®Google Scholar
• SHOBACK DM, FIREK AF, MIMS RB et al.: An evaluation of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism (PHPT). J Bone Mineral Res. (2001) 16\(Supp1.1):S503.
   Google Scholar
• PEACOCK M, SHOBACK DM, GRETH E et al.: The calcimimetic AMG-073 reduces serum calcium (Ca) in patients with primary hyperparathyroidism. J Bone Mineral Res. (2001) 16\(Suppl. 1):5163.
   Google Scholar
• LINDBERG JS, MOE SM, GOODMAN WG et al.: The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. (2003) 63(1):248–254.
   PubMed Web of Science ®Google Scholar
• QUARLES LD, SHERRARD DJ, ADLER S et al.: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am. Soc. NephroL (2003) 14(3):575–583.
   PubMed Web of Science ®Google Scholar
• GOODMAN WG, HLADIK GA, TURNER SA et al.: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am. Soc. NephroL (2002) 13(4):1017–1024.
   PubMed Web of Science ®Google Scholar
• BLOCK GA, COYNE DW, GOODMAN WG et al.: The calcimimetic AMG 073: a potential novel therapy for secondary hyperparathyroidism (SHPT).J. Am. Soc. Nephrol. (2002) 13:572A.
   Google Scholar
• QUARLES LD, SPIEGEL DM, CURZI M et al.: The effect of one-year treatment with the calcimimetic AMG 073 on bone health in ESRD patients with secondary hyperparathyroidism (SHPT). J. Am. Soc. Nephrol. (2002) 13:572A–573A.
   Google Scholar
• MOE SM, SPRAGUE SM, ADLER S et al.: Two-years treatment with the calcimimetic AMG 073 in hemodialysis patients with secondary hyperparathyroidism (SHPT). J. Am. Soc. Nephrol. (2002) 13:572A.
   Web of Science ®Google Scholar
• DRUEKE T, CUNNINGAM J, GOODMAN WG et al.: Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073.1 Am. Soc. Nephrol. (2001) 12:764A.
   Google Scholar
• COLLINS MT, SKARULIS MC, BILEZIKIAN JP et al.: Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. j Gun. Endocrinol. Metab. (1998) 83(4):1083–1088.
   PubMed Web of Science ®Google Scholar
• PEACOCK M: Normalization of hypercalcemia with the calcimimetic AMG 073 in a patient with metastatic parathyroid cancer. j Bone Mineral Res. (2002) 17:S381.
   PubMed Web of Science ®Google Scholar
• SILVERB ERG SJ, FAIMAN C, BILEZIKIAN JP et al.: The effects of cinacalcet HC1 (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTX. j Bone Mineral Res. (2003) 18\(Suppl. 1):5171.
   Google Scholar
• RUB IN M, SLINEY J, McCARY LC et al.: Effective management of severe hypercalcemia with the calcimimetic cinacalcet HC1 in patients with parathyroid carcinoma. J Bone Mineral Res. (2003) 18\(Suppl. 2):5392.
   Google Scholar
• URENA P: Parathyroid gland, calcium receptor and calcimimetics. Nephrologie (2002) 23(4):151–164.
   PubMedGoogle Scholar
• OLGAARD K, LEWIN E: Prevention of uremic bone disease using calcimimetic compounds. Ann. Rev Med. (2001) 52:203–220.
   PubMed Web of Science ®Google Scholar
• QUARLES LD, SHERRARD DJ, ADLER S et al.: The calcimimetic AMG 073 reduces PTH and Ca x P in patients with secondary hyperparathyroidism (SHPT). J Am. Soc. Nephrol. (2001) 12:771A.
   Google Scholar
• WADA M, NAGANO N, FURUYA Y et al.: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int. (2000) 57(1):50–58.
   PubMed Web of Science ®Google Scholar
• URENA P, FRAZAO JM: Calcimimetic agents: review and perspectives. Kidney Int. (2003) 85:S91–S96.
   Google Scholar
• DREWS J: Drug discovery: a historical perspective. Science (2000) 287(5460):1960–1964.
   PubMed Web of Science ®Google Scholar
• MAP, ZEMMEL R: Value of novelty? Nat. Rev. Drug Discov. (2002) 1(8):571–572.
   PubMed Web of Science ®Google Scholar
• FANG Y, LAHIRI J, PICARD L: G protein-coupled receptor microarrays for drug discovery. Drug Discovery (2003) 8(16):755–761. Affiliation Aberto Falchetti Department of Internal Medicine, University of Florence and Centro di Riferimento Regionale su Tumori Endocrini Ereditari, Azienda Ospedaliera Careggi, Florence, Italy Tel: +39 055 4271 502; Fax: +39 055 4271 506; E-mail: [email protected]
   Google Scholar